Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Thomas

Showing results (601-610 of 792) with videos related to

Pageof 80
Sort By:
Oncology Research and Treatment|October 22, 2019
Symptoms and Needs of Patients with Advanced Lung Cancer: Early Prevalence AssessmentJonas Kuon, Jeannette Vogt, Anja Mehnert, et al.
Future Oncology (London, England)|May 11, 2026
Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocolsNeal D Shore, Karim Fizazi, Michael Thomas Schweizer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2010
Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancerJoan H Schiller, Joachim von Pawel, Philipp Schütt, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2022
Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgeryTobias Boch, Nikolaj Frost, Linna Sommer, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancerLars Henning Schmidt, Janine Stucke-Ring, Caroline Brand, et al.
Translational Lung Cancer Research|December 15, 2022
Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approachLaura V Klotz, Hans Hoffmann, Rajiv Shah, et al.
Frontiers in Oncology|July 16, 2021
Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung CancerLea Daniello, Mariam Elshiaty, Farastuk Bozorgmehr, et al.
Cancers|April 29, 2020
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 InhibitorsStephan Rheinheimer, Claus-Peter Heussel, Philipp Mayer, et al.
Biorxiv : the Preprint Server for Biology|August 9, 2020
Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M<sup>pro</sup> and cathepsin LMichael Dominic Sacco, Chunlong Ma, Panagiotis Lagarias, et al.
Cancers|April 16, 2020
Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced StagesFlorian Janke, Farastuk Bozorgmehr, Sabine Wrenger, et al.
Pageof 80

Showing results (601-610 of 792) with videos related to

Sort By:
Pageof 80
Oncology Research and Treatment|October 22, 2019
Symptoms and Needs of Patients with Advanced Lung Cancer: Early Prevalence AssessmentJonas Kuon, Jeannette Vogt, Anja Mehnert, et al.
Future Oncology (London, England)|May 11, 2026
Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocolsNeal D Shore, Karim Fizazi, Michael Thomas Schweizer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2010
Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancerJoan H Schiller, Joachim von Pawel, Philipp Schütt, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2022
Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgeryTobias Boch, Nikolaj Frost, Linna Sommer, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancerLars Henning Schmidt, Janine Stucke-Ring, Caroline Brand, et al.
Translational Lung Cancer Research|December 15, 2022
Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approachLaura V Klotz, Hans Hoffmann, Rajiv Shah, et al.
Frontiers in Oncology|July 16, 2021
Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung CancerLea Daniello, Mariam Elshiaty, Farastuk Bozorgmehr, et al.
Cancers|April 29, 2020
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 InhibitorsStephan Rheinheimer, Claus-Peter Heussel, Philipp Mayer, et al.
Biorxiv : the Preprint Server for Biology|August 9, 2020
Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M<sup>pro</sup> and cathepsin LMichael Dominic Sacco, Chunlong Ma, Panagiotis Lagarias, et al.
Cancers|April 16, 2020
Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced StagesFlorian Janke, Farastuk Bozorgmehr, Sabine Wrenger, et al.
Pageof 80